Valeant Pharmaceuticals International Inc. pledged to provide hospitals up to 40% in discounts on two of the company's medicines, whose controversial high prices have gotten it into hot water. Meanwhile, short-seller Andrew Left said he was now long on Valeant, while T. Rowe Price sold 90% of its shares in the Canadian drug firm.
Valeant Pharmaceuticals International Inc. on May 16 said it was offering hospitals discounts of at least 10% and up to 40% for its drugs Nitropress (sodium nitroprusside) and Isuprel (isoprenaline), whose controversial price hikes had gotten the firm into hot water with lawmakers and federal investigators.
It's unclear whether the move will put more pressure on other drug makers to follow suit – especially since Valeant...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
